Adaptive Biotechnologies ADPT Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Business | |||||
| Immune Medicine Business | $64.64M+93.4% | $33.43M-50.5% | $67.54M-31.2% | $98.16M— | |
| Mrd Business | $212.33M+45.9% | $145.53M+41.6% | $102.74M+17.9% | $87.14M— | |
| Adjusted Ebitda by Business | |||||
| Mrd Business | $15.19M+137% | -$41.22M+53.6% | -$88.84M-46.9% | -$60.5M— | |
| Research And Development Expense by Business | |||||
| Immune Medicine Business | $55.86M-6.5% | $59.71M-23.3% | $77.87M-29.2% | $109.99M— | |
| Mrd Business | $35.03M-14.0% | $40.74M-3.3% | $42.15M+32.7% | $31.77M— | |
| Revenue by Product | |||||
| Collaboration Revenue | $41.28M+207% | $13.45M-68.4% | $42.58M-35.9% | $66.39M+4.3% | |
| Regulatory Milestone Revenue | $19.5M+56.0% | $12.5M— | —— | $6M-40.0% | |
| Service And Licensing Revenue | $23.36M+16.9% | $19.98M-20.0% | $24.96M— | —— | |
| Service | $192.83M+45.0% | $133.03M+29.5% | $102.74M+26.6% | $81.14M+44.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Adaptive Biotechnologies break its business down?
- Adaptive Biotechnologies (ADPT) reports revenue by business across 2 parts — Immune Medicine Business and Mrd Business. Each is extracted from the segment footnotes and tracked over time.
- Where does Adaptive Biotechnologies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Adaptive Biotechnologies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
